UY27074A1 - Derivados de aminotriazolopiridina - Google Patents

Derivados de aminotriazolopiridina

Info

Publication number
UY27074A1
UY27074A1 UY27074A UY27074A UY27074A1 UY 27074 A1 UY27074 A1 UY 27074A1 UY 27074 A UY27074 A UY 27074A UY 27074 A UY27074 A UY 27074A UY 27074 A1 UY27074 A1 UY 27074A1
Authority
UY
Uruguay
Prior art keywords
aminotriazolopiridine
derivatives
compounds
receptor
pharmaceutically acceptable
Prior art date
Application number
UY27074A
Other languages
English (en)
Inventor
M H Nettekoven
B Brodbeck
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY27074A1 publication Critical patent/UY27074A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención describe compuestos de fórmula general: I. Y las sales de adición ácida farmacéuticamente aceptables en donde R1. R2 y X están definidos en la reivindicación I. Los compuestos tienen una buena afinidad por el receptor de adenosina y se pueden usar además en el tratamiento de enfermedades, relacionadas con este receptor.
UY27074A 2000-12-15 2001-12-14 Derivados de aminotriazolopiridina UY27074A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00127567 2000-12-15

Publications (1)

Publication Number Publication Date
UY27074A1 true UY27074A1 (es) 2002-07-31

Family

ID=8170683

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27074A UY27074A1 (es) 2000-12-15 2001-12-14 Derivados de aminotriazolopiridina

Country Status (21)

Country Link
US (1) US6506772B1 (es)
EP (1) EP1347974B1 (es)
JP (1) JP4049672B2 (es)
KR (1) KR100540628B1 (es)
CN (1) CN1221551C (es)
AR (1) AR031799A1 (es)
AT (1) ATE281456T1 (es)
AU (2) AU2002231674B2 (es)
BR (1) BR0116193A (es)
CA (1) CA2437006C (es)
DE (1) DE60106974T2 (es)
DK (1) DK1347974T3 (es)
ES (1) ES2230387T3 (es)
GT (1) GT200100253A (es)
MX (1) MXPA03005334A (es)
PA (1) PA8534701A1 (es)
PE (1) PE20020666A1 (es)
PT (1) PT1347974E (es)
UY (1) UY27074A1 (es)
WO (1) WO2002048145A1 (es)
ZA (1) ZA200304481B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL370067A1 (en) * 2001-10-08 2005-05-16 F.Hoffmann-La Roche Ag 8-amino-[1,2,4]triazolo[1,5-a]pyridine-6-carboxylic acid amide
WO2004041285A1 (en) * 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
KR101412339B1 (ko) 2004-07-15 2014-06-25 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를차단하기 위한 용도
AU2007272009A1 (en) * 2006-07-12 2008-01-17 Syngenta Limited Triazolopyridine derivatives as herbicides
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8815894B2 (en) * 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
CA2760837C (en) * 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
EP2757882B1 (en) 2011-09-22 2020-11-04 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
WO2013043520A1 (en) * 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
WO2020054712A1 (ja) * 2018-09-12 2020-03-19 日本化薬株式会社 有害生物防除剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356894A (en) 1990-05-29 1994-10-18 Rodney Peter W Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist
GB9226735D0 (en) 1992-12-22 1993-02-17 Ici Plc Azole derivatives
WO1999043678A1 (fr) 1998-02-24 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Medicaments et prophylaxie contre la maladie de parkinson
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives

Also Published As

Publication number Publication date
AR031799A1 (es) 2003-10-01
JP4049672B2 (ja) 2008-02-20
AU3167402A (en) 2002-06-24
CA2437006A1 (en) 2002-06-20
MXPA03005334A (es) 2004-04-02
DE60106974D1 (de) 2004-12-09
CN1486314A (zh) 2004-03-31
EP1347974B1 (en) 2004-11-03
PE20020666A1 (es) 2002-07-27
PA8534701A1 (es) 2002-08-26
KR20030061446A (ko) 2003-07-18
EP1347974A1 (en) 2003-10-01
DK1347974T3 (da) 2005-03-14
ATE281456T1 (de) 2004-11-15
WO2002048145A1 (en) 2002-06-20
AU2002231674B2 (en) 2006-07-06
ZA200304481B (en) 2004-09-09
JP2004521096A (ja) 2004-07-15
CN1221551C (zh) 2005-10-05
PT1347974E (pt) 2005-02-28
US6506772B1 (en) 2003-01-14
BR0116193A (pt) 2003-09-23
ES2230387T3 (es) 2005-05-01
CA2437006C (en) 2009-10-27
GT200100253A (es) 2002-07-31
DE60106974T2 (de) 2005-11-03
KR100540628B1 (ko) 2006-01-11

Similar Documents

Publication Publication Date Title
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
UY26754A1 (es) Derivados de la 1, 3, 8, -triaza-spiro (4,5) decan-4-ona
UY26782A1 (es) Derivados del benzotiazol
ECSP088549A (es) Nuevos derivados de pirrol fusionado
PA8591701A1 (es) Derivados de pirrolopirimidina
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
CY1116103T1 (el) Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης
UY26851A1 (es) Derivados de la 4-fenilpiridina
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
NO20060973L (no) Pyridylderivater og deres anvendelse som tempeutiske midler
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
PA8578601A1 (es) Derivados de 2,2- difenil-benzodioxol
MA27040A1 (fr) Nucleosides substitues en 4'
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
HN2002000028A (es) Pirimidinas inhibidoras de metaloproteinasas
DOP2001000170A (es) Derivados de tiofeno utiles como agentes anticancesoros
ECSP055844A (es) Nuevos compuestos triciclicos
SE0402762D0 (sv) Indazole sulphonamide derivatives
BRPI0411891A (pt) pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3
DE60121461D1 (de) Kondensierte pyridoindolderivate
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141111